Get started
Author

Marta Mora-Rillo

Observed names: M Mora, M Mora-Rillo, M Mora‐Rillo, M. Mora, M. Mora Rillo, M. Mora-Rillo, Marta Mora, Marta Mora Rillo
Observed institutions: Cedars-Sinai Medical Center, St Thomas' Hospital, Mayo Clinic, John Muir Health, Tel Aviv University, Queen's University, Tel Aviv Sourasky Medical Center, Hospital Universitario La Paz, El Camino Hospital, Instituto de Salud Carlos III, Hospital de Sant Pau, Israel Ministry of Health, Hospital La Paz Institute for Health Research, Centro de Investigación Biomédica en Red, Sutter Santa Rosa Regional Hospital, European Society of Clinical Microbiology and Infectious Diseases, Comunidad de Madrid, Good Samaritan Hospital, Centre Hospitalier de l’Université de Montréal, UC Davis Health, Good Samaritan Hospital, Centro de Investigación Biomédica en Red Enfermedades Infecciosas, Universidad Autónoma de Madrid, Bernhard Nocht Institute for Tropical Medicine
ORCID: 0000-0002-2735-5931
Observed ORCID: 0000-0002-2735-5931
OpenAlex ID: A5010501333
Compassionate Use of Remdesivir for Patients with Severe Covid-19
2020 · Jonathan Grein, Norio Ohmagari, et al. · New England Journal of Medicine · 2,736
PDF
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
2017 · Belén Gutiérrez-Gutiérrez, Elena Salamanca, et al. · The Lancet Infectious Diseases · 512
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain
2020 · Juan Berenguer, Juan Berenguer, et al. · Clinical Microbiology and Infection · 401
PDF
Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms
2016 · Elizabeth Temkin, Julian Torre-Cisneros, et al. · Antimicrobial Agents and Chemotherapy · 254
PDF
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
2021 · François-Xavier Lescure, Hitoshi Honda, et al. · The Lancet Respiratory Medicine · 246
PDF
Autochthonous Crimean–Congo Hemorrhagic Fever in Spain
2017 · Anabel Negredo, Fernando de la Calle-Prieto, et al. · New England Journal of Medicine · 221
PDF
A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
2016 · Belén Gutiérrez-Gutiérrez, Salvador Pérez-Galera, et al. · Antimicrobial Agents and Chemotherapy · 152
Prospective Multicenter Study of Carbapenemase-Producing Enterobacteriaceae from 83 Hospitals in Spain Reveals High In Vitro Susceptibility to Colistin and Meropenem
2015 · Jesús Oteo, Adriana Ortega, et al. · Antimicrobial Agents and Chemotherapy · 150
PDF
Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge
2012 · C. Navarro-San Francisco, M. Mora-Rillo, et al. · Clinical Microbiology and Infection · 130
PDF
Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain
2015 · Marta Mora-Rillo, Marta Arsuaga, et al. · The Lancet Respiratory Medicine · 129
A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae
2016 · Belén Gutiérrez-Gutiérrez, Elena Salamanca, et al. · Mayo Clinic Proceedings · 122
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study
2021 · Belén Gutiérrez-Gutiérrez, María Dolores del Toro, et al. · The Lancet Infectious Diseases · 95
PDF
Infections caused by OXA-48-producing Klebsiella pneumoniae in a tertiary hospital in Spain in the setting of a prolonged, hospital-wide outbreak
2012 · J. R. Pano-Pardo, G. Ruiz-Carrascoso, et al. · Journal of Antimicrobial Chemotherapy · 89
PDF
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
2022 · Karin Hardt, An Vandebosch, et al. · The Lancet Infectious Diseases · 83
PDF
Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain
2015 · Zaira R. Palacios-Baena, Jesús Oteo, et al. · Journal of Infection · 82
Impact of virulence genes on sepsis severity and survival in Escherichia coli bacteremia
2015 · Marta Mora-Rillo, Natalia Fernández-Romero, et al. · Virulence · 81
PDF
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels
2021 · ACTIV-3/TICO Bamlanivimab Study Group*, Jens D. Lundgren, et al. · Annals of Internal Medicine · 77
PDF
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19
2022 · ACTIV-3/TICO Study Group, Angela J. Rogers, et al. · Annals of Internal Medicine · 60
PDF
Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae: Results From the INCREMENT Cohort
2017 · Zaira Raquel Palacios-Baena, Belén Gutiérrez-Gutiérrez, et al. · Clinical Infectious Diseases · 58
PDF
SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy
2021 · C Ferreras, B Pascual-Miguel, et al. · Frontiers in Cell and Developmental Biology · 56
PDF
Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study
2016 · Belén Gutiérrez-Gutiérrez, Robert A. Bonomo, et al. · Journal of Antimicrobial Chemotherapy · 50
PDF
Metabolic syndrome: prevalence, associated factors, and C-reactive protein
2008 · Maria A. Martínez, Juan G. Puig, et al. · Metabolism · 48
Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae
2018 · A. Russo, M. Falcone, et al. · International Journal of Antimicrobial Agents · 47
PDF
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
2023 · Marius Trøseid, José R. Arribas, et al. · Critical Care · 43
PDF
Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)
2021 · A. Pérez-Martínez, M. Mora-Rillo, et al. · EClinicalMedicine · 36
PDF
Works count: 108
Citation count: 6,537
H-index: 27
I10-index: 51
Year
Topic
Type